Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 62.50
Bid: 60.00
Ask: 65.00
Change: 0.00 (0.00%)
Spread: 5.00 (8.333%)
Open: 62.50
High: 62.50
Low: 62.50
Prev. Close: 62.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wanda Forms Scientific Advisory Board

16 Mar 2016 07:00

RNS Number : 2148S
NetScientific PLC
16 March 2016
 

 

 

 ("NetScientific" or the "Group")

 

 

Wanda Forms Scientific Advisory Board to Provide Strategic Guidance

London, UK - 16 March 2016 - NetScientific plc (AIM: NSCI), the transatlantic biomedical and healthcare technology group, notes its Digital Health Portfolio company, Wanda, has announced the formation of a Scientific Advisory Board to provide thought leadership and strategic guidance to the Wanda management team. Board members include distinguished physicians, health economics scientists, and technologists committed to advancing clinical outcomes for individuals with chronic disease.

Commenting on the news, NetScientific's Chief Executive Officer, Francois R. Martelet said: "Wanda's technology has broad potential to simplify and improve the lives of people confronted with chronic conditions and, in the near term, to help patients with Congestive Heart Failure and their physicians to monitor risk and predict and prevent readmission to hospital. The calibre of the new SAB members is testament to the quality of the Wanda platform and we look forward to their input as Wanda develops into a world-leading digital health business."

The full text of the announcement issued by Wanda on 15 March 2016 can be found below:

 

Wanda Forms Scientific Advisory Board to Provide Strategic Guidance

 

Inaugural Members include clinical and technology experts committed to advancing the management of chronic disease

 

SAN FRANCISCO - March 15, 2016 Wanda today announced the formation of a Scientific Advisory Board to provide thought leadership and strategic guidance to the Wanda management team. Board members include distinguished physicians, health economics scientists, and technologists committed to advancing clinical outcomes for individuals with chronic disease.

 

"The inaugural members of Wanda's Scientific Advisory Board include an impressive mix of visionaries and opinion leaders across a variety of disciplines," said Wanda CCO Mark Heinemeyer. "All are passionate about advancing state-of-the-art chronic disease management."

 

"This group shares Wanda's belief in the power of excellent design to improve connections with patients, to engage loved ones, and to enhance outcomes," added Wanda CTO Foad Dabiri. "We look forward to working with these industry leaders as we continue to accelerate the development and implementation of the Wanda platform."

 

Wanda's new Scientific Advisory Board members include:

 

Constanzo DiPerna, MD, MBA - Dr. DiPerna is Medical Director of Dignity Health Cancer Institute of Greater Sacramento; Chief of Thoracic Surgery and Medical Director of Chest Disease for Mercy San Juan Medical Center; and Chief of Thoracic Surgery for Dignity Health Mercy Medical Group Sacramento. Dr. DiPerna is also the founder of ONCOVERSE LLC Global Center Network.

 

Clyde E. Wesp, Jr, MD, MAOM - Dr. West is Executive Clinical Strategist at Jacobus Consulting, where he is dedicated to improving the quality and safety of care along the continuum through clinical decision support, evidence-based medicine, and strategic transformation of clinical processes. He is currently a USC Adjunct Professor at the Sol Price School of Public Policy where he teaches Masters students in the area of population health and related clinical issues.

 

Janki Shah, MD - Dr. Shah is the founder and director of the UCLA Northwest Valley Women's Heart Health Program, which strives to ensure that women embrace cardiac screening and early detection of cardiovascular disease, as well as to provide a unique female focus on the education, prevention, early detection, treatment, and management of heart disease. Dr. Shah serves of the Board of Directors of the American Heart Association - Greater Los Angeles.

 

Jeff Moreland, BSN - Moreland is CEO and Chief Patient Officer for Patient Engagement Advisors (PEA). He created PEA as a self-funded effort, driven from the results of a Cleveland Clinic research project that considered the impact of care process gaps created when patients are transitioned across the healthcare continuum. Inc. Magazine has recognized PEA as one of the fastest growing companies in America and The American Business Awards has acknowledged PEA for its patient-focused technology innovation.

 

"Wanda is taking an innovative, science-based approach to solving some of healthcare's toughest and most longstanding problems," said Dr. Shah. "I am honored to serve on Wanda's Scientific Advisory Board and help the company improve the management of chronic disease."

 

Wanda's digital health platform connects the consumer and the clinical care team in a virtual network, intelligently collects critical vital and symptom information, and applies proven machine learning analytics to deliver ongoing risk analysis and decision support. Individuals are equipped to take better care of themselves and clinicians are able to more efficiently engage with those consumers when they need the most assistance maintaining a high quality of life at home.

 

The Wanda solution includes the unique easy-to-use Wanda app running on a smart phone or tablet. The app regularly interacts with an individual to simultaneously capture symptom information and to detect important vital sign measurements. Collected data is securely stored and analyzed on Wanda's cloud-based analytics platform, which utilizes machine learning to help individuals manage their health issues. Should intervention by a healthcare professional be required, Wanda identifies the appropriate provider to guide an appropriate intervention, avoiding potential deterioration of the individual's health condition that could result in disruptive and costly hospitalization.

 

# # #

 

About Wanda

 

San Francisco-based Wanda is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning in place of conventional technologies and by enabling clinicians to make more informed care decisions. Wanda recognizes that remote monitoring and algorithms cannot save lives or reduce hospitalizations unless the individual and their caregivers are promptly informed and highly engaged. Through the collaboration of data science and applied medical research, Wanda has proven that its inline analytics predict preventable events much better than conventional methods. Wanda serves as a diligent companion, providing encouragement and intelligent visual guidance that simplifies and improves lives, while simultaneously helping organizations reduce their care delivery costs. Wanda is a NetScientific portfolio company. More information about Wanda can be found HERE.

 

About NetScientific

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment.

 

For more information, please visit the website at www.netscientific.net

 

 

- Ends -

 

Contact Details

NetScientific

François R. Martelet, M.D., CEO

Mark Nanovich, Interim CFO

 

Tel: +44 (0)20 3514 1800

 

Investec (NOMAD and broker)

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

 

Consilium Strategic Communications

Mary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton

 

Tel: +44 (0)20 3709 5700

Email: netscientific@consilium-comms.com

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRALFFIFVFIELIR
Date   Source Headline
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update
30th Mar 20233:51 pmRNSPDS Update
28th Mar 20233:50 pmRNSPDS Business Update and 2022 Financial Results
28th Feb 20237:00 amRNSRelated party loan to ProAxsis Limited
27th Feb 20233:28 pmRNSPDS completes FDA meeting for triple combination
10th Feb 20232:05 pmRNSSecond Price Monitoring Extn
10th Feb 20232:00 pmRNSPrice Monitoring Extension
10th Feb 202311:05 amRNSSecond Price Monitoring Extn
10th Feb 202311:00 amRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSBoard Change
3rd Jan 20231:31 pmRNSPDS Announces Exclusive Global License Agreement
28th Dec 20223:05 pmRNSPDS Biotech: Median Overall Survival announcement
16th Dec 20227:00 amRNSPDS: HPV16 Head and Neck Cancer announcement
12th Dec 20222:00 pmRNSBoard Changes; Options; Co-Investment Agreement
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.